0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Original Investigation |  ONLINE FIRST
Vinay Prasad, MD, MPH; Chul Kim, MD, MPH; Mauricio Burotto, MD; et al.
JAMA Intern Med. Published online June 22, 2015. doi:10.1001/jamainternmed.2015.2829
Includes: Supplemental Content

Special Communication | 
Gary Schwitzer, BA
JAMA Intern Med. 2014;174(7):1183-1186. doi:10.1001/jamainternmed.2014.1359.
Includes: Supplemental Content

Viewpoint | 
Susan Desmond-Hellmann, MD, MPH
JAMA Intern Med. 2013;173(12):1051-1052. doi:10.1001/jamainternmed.2013.826.

Original Investigation |  FREE
Gregg H. Goldin, MD; Nathan C. Sheets, MD; Anne-Marie Meyer, PhD; et al.
JAMA Intern Med. 2013;173(12):1136-1143. doi:10.1001/jamainternmed.2013.1020.
Includes: Supplemental Content

Invited Commentary | 
Matthew R. Cooperberg, MD, MPH
JAMA Intern Med. 2013;173(12):1143-1144. doi:10.1001/jamainternmed.2013.6755.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Invited Commentary  | 
Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations
Pieter Sonneveld, MD, PhD
JAMA Oncology
Original Investigation  | 
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, MD; Mark Roschewski, MD; Adriana Zingone, MD, PhD; et al.
JAMA Oncology
Viewpoint  | 
Having “Skin in the Game” and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs
Hagop Kantarjian, MD; Michael S. Mathisen, PharmD; Jeffrey H. Lipton, PhD, MD
JAMA Oncology
Brief Report  | 
Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib
Kenar D. Jhaveri, MD; Vipulbhai Sakhiya, MBBS; Steven Fishbane, MD